Apogee Therapeutics将于2026年1月6日召开电话会议 公布Apg777针对轻中度哮喘患者的1B期临床试验中期结果及2026年预期里程碑

美股速递
Jan 06

Apogee Therapeutics宣布,公司计划于2026年1月6日举行专题电话会议,重点披露其候选药物Apg777在轻中度哮喘患者中开展的1B期临床试验的中期研究数据。此次会议还将详细阐述公司为2026年规划的关键发展节点与战略目标。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10